ADC Therapeutics SA (ADCT) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 78.9% versus a loss of 65.0%. Over five years, SLGL leads with a -24.6% price change compared with -93.8% for ADCT. Sol-Gel Technologies is the larger company by market cap ($234.8 million vs $231.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | SLGL |
|---|---|---|
| Share price | $1.82 | $71.72 |
| Market cap | $231.72M | $234.81M |
| 1-day change | +14.13% | +1.96% |
| YTD return | -54.96% | +66.92% |
| 1-year return | -64.98% | +78.89% |
| 5-year return | -93.76% | -24.57% |
| EPS (TTM) | $-0.60 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $97.97 |
| 52-week low | $0.78 | $28.81 |
| Distance from 52-week high | -63.55% | -26.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +83.47% | +112.63% |
| Average volume | 1.43M | 55.55K |
| Shares outstanding | 127.67M | 3.27M |
| Employees | 188 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed ADCT by 143.9 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
ADCT vs SLGL FAQ
Which is bigger, ADC Therapeutics SA or Sol-Gel Technologies?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $234.81M compared with $231.72M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or SLGL?
SLGL returned +78.89% over the past 12 months, compared with -64.98% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.